TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from ImmuPharma ( (GB:IMM) ) is now available.
ImmuPharma PLC has announced an extension of warrants in Incanthera to 30 September 2025, allowing the company to potentially benefit from investment gains if Incanthera’s business development positively impacts its share price. This agreement, which includes a profit-sharing mechanism, is seen as advantageous for both companies and has been treated as a related party transaction due to the involvement of Tim McCarthy, who holds positions in both companies.
More about ImmuPharma
ImmuPharma PLC is a specialty biopharmaceutical company focused on discovering and developing peptide-based therapeutics. Its portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives, with a lead program, P140, targeting Systemic Lupus Erythematosus (SLE) and Chronic Idiopathic Demyelinating Polyneuropathy (CIDP).
YTD Price Performance: 145.00%
Average Trading Volume: 10,519,224
Technical Sentiment Signal: Hold
Current Market Cap: £14.69M
For a thorough assessment of IMM stock, go to TipRanks’ Stock Analysis page.